HK Stock Market Move | CF PHARMTECH (02652) rose more than 21% in midday trading, with the innovative research and development pipeline for high-end respiratory system formulations entering a period of accelerated harvest.

CF PHARMTECH (02652) surged more than 21% in early trading, and as of the time of writing, it was up 14.54%, trading at 28.2 Hong Kong dollars with a turnover of 81.9611 million Hong Kong dollars. On the news front, recently, CF PHARMTECH announced that its self-developed inhaled powder spray ICF001 (a chemically modified new drug in class 2.1) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) has had its new drug clinical trial application (IND) formally accepted by the National Medical Products Administration (NMPA) of China. Following ICF004, this is another inhaled dosage form improved innovative drug that has been accepted, marking the acceleration in the harvest period of the company's innovative research and development pipeline in the high-end respiratory system formulation field. Starting on March 9, CF PHARMTECH has officially been included in the list of securities eligible for trading through the Stock Connect program. The board of directors expects that this inclusion will help to expand the company's shareholder base and enhance the trading liquidity of the company's H shares. Huaxin Securities recently pointed out in a research report that the company continues to focus on innovation, and its new drug for treating PAH is expected to have its IND filed within the year. Considering the company's continuous application for clinical trials of innovative drugs with global patents, they have given a "buy" investment rating.